Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells

British Journal of Pharmacology

Volumn 173, Issue 3, 2016, Pages 484-496

  Sarwar, M ^a   Samuel, C S ^a   Bathgate, R A ^b   Stewart, D R ^c   Summers, R J ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Corthera Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; CYCLIC AMP; CYCLIC GMP; INDOMETACIN; N(G) NITROARGININE; PROSTANOID; SERELAXIN; 1H-(1,2,4)OXADIAZOLO(4,3-A)QUINOXALIN-1-ONE; G PROTEIN COUPLED RECEPTOR; OXADIAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; RECEPTOR; RECOMBINANT PROTEIN; RELAXIN; RXFP1 PROTEIN, HUMAN; SERELAXIN PROTEIN, HUMAN;

ARTICLE; BIOACCUMULATION; CELL STIMULATION; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; GAP JUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; CORONARY BLOOD VESSEL; CYTOLOGY; METABOLISM; SMOOTH MUSCLE CELL; UMBILICAL ARTERY; UMBILICAL VEIN;

COCULTURE TECHNIQUES; CORONARY VESSELS; CYCLIC AMP; CYCLIC GMP; ENDOTHELIAL CELLS; HUMANS; INDOMETHACIN; MYOCYTES, SMOOTH MUSCLE; NITROARGININE; OXADIAZOLES; QUINOXALINES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; RELAXIN; SIGNAL TRANSDUCTION; UMBILICAL ARTERIES; UMBILICAL VEINS;

EID: 84956752656     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13371     Document Type: Article

References (53)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexiou K, Wilbring M, Matschke K, Dschietzig T, (2013). Relaxin protects rat lungs from ischemia-reperfusion injury via inducible NO synthase: role of ERK-1/2, PI3K, and forkhead transcription factor FKHRL1. PLoS One 8: e75592.
4. Bani Sacchi T, Bigazzi M, Bani D, Mannaioni PF, Masini E, (1995). Relaxin-induced increased coronary flow through stimulation of nitric oxide production. Br J Pharmacol 116: 1589-1594.
5. Bani D, Baccari MC, Nistri S, Calamai F, Bigazzi M, Sacchi TB, (1999). Relaxin up-regulates the nitric oxide biosynthetic pathway in the mouse uterus: involvement in the inhibition of myometrial contractility. Endocrinology 140: 4434-4441.
6. Bani D, Ballati L, Masini E, Bigazzi M, Sacchi TB, (1997). Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs. Endocrinology 138: 1909-1915.
7. Bani D, Failli P, Bello MG, Thiemermann C, Bani Sacchi T, Bigazzi M, et al., (1998). Relaxin activates the l -arginine-nitric oxide pathway in vascular smooth muscle cells in culture. Hypertension 31: 1240-1247.
8. Bani D, Masini E, Bello MG, Bigazzi M, Sacchi TB, (1995a). Relaxin activates the l -arginine-nitric oxide pathway in human breast cancer cells. Cancer Res 55: 5272-5275.
9. Bani D, Nistri S, Quattrone S, Bigazzi M, Bani Sacchi T, (2001). The vasorelaxant hormone relaxin induces changes in liver sinusoid microcirculation: a morphologic study in the rat. J Endocrinol 171: 541-549.
10. Bani G, Maurizi M, Bigazzi M, Bani Sacchi T, (1995b). Effects of relaxin on the endometrial stroma. Studies in mice. Biol Reprod 53: 253-262.
11. Bigazzi M, Del Mese A, Petrucci F, Casali R, Novelli GP, (1986). The local administration of relaxin induces changes in the microcirculation of the rat mesocaecum. Acta Endocrinol 112: 296-299.
12. Boccalini G, Sassoli C, Formigli L, Bani D, Nistri S, (2015). Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch-1 pathway. FASEB J 29: 239-249.
13. Bolton TB, Lang RJ, Takewaki T, (1984). Mechanisms of action of noradrenaline and carbachol on smooth muscle of guinea-pig anterior mesenteric artery. J Physiol 351: 549-572.
14. Chan S-L, Cipolla MJ, (2011). Relaxin causes selective outward remodeling of brain parenchymal arterioles via activation of peroxisome proliferator-activated receptor-γ. FASEB J 25: 3229-3239.
15. Chan S-L, Sweet JG, Cipolla MJ, (2013). Treatment for cerebral small vessel disease: effect of relaxin on the function and structure of cerebral parenchymal arterioles during hypertension. FASEB J 27: 3917-3927.
16. Conrad KP, Debrah DO, Novak J, Danielson LA, Shroff SG, (2004). Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats. Endocrinology 145: 3289-3296.
17. Conrad KP, Shroff SG, (2011). Effects of relaxin on arterial dilation, remodeling, and mechanical properties. Curr Hypertens Rep 13: 409-420.
18. Danielson LA, Conrad KP, (2003). Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats. J Appl Physiol 95: 1509-1514.
19. Danielson LA, Sherwood OD, Conrad KP, (1999). Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 103: 525-533.
20. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG, (2005). Relaxin increases cardiac output and reduces systemic arterial load in hypertensive rats. Hypertension 46: 745-750.
21. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP, (2006). Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 147: 5126-5131.
22. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K, (2003). Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kappaB. Circ Res 92: 32-40.
23. Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB, et al., (2002). Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J 16: 252-254.
24. Figueroa XF, Duling BR, (2009). Gap junctions in the control of vascular function. Antioxid Redox Signal 11: 251-266.
25. Fisher CJ, (2009). Relaxin: a new cardiovascular hormone in humans? Comparative potency and mechanisms of action. MD Thesis, University of Glasgow.
26. Furchgott RF, Vanhoutte PM, (1989). Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007-2018.
27. Furchgott RF, Zawadzki JV, (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376.
28. Ganz P, Davies PF, Leopold JA, Gimbrone MA, Alexander RW, (1986). Short- and long-term interactions of endothelium and vascular smooth muscle in coculture: effects on cyclic GMP production. Proc Natl Acad Sci U S A 83: 3552-3556.
29. Hollenberg SM, (2007). Vasodilators in acute heart failure. Heart Fail Rev 12: 143-147.
30. Jelinic M, Leo C-H, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME, et al., (2013). Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 28: 275-287.
31. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP, (2003). Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93: 1249-1257.
32. Leo C-H, Jelinic M, Parkington HC, Tare M, Parry LJ, (2013). Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 3: e000493-e000493.
33. Longo M, Jain V, Vedernikov YP, Garfield RE, Saade GR, (2003). Effects of recombinant human relaxin on pregnant rat uterine artery and myometrium in vitro. Am J Obstet Gynecol 188: 9-9.
34. Lüscher TF, (1990). Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels. Lung 168 (Suppl): 27-34.
35. Lüscher TF, Tanner FC, (1992). Endothelial regulation of vascular tone and growth. Am J Hypertens 6: 283-293.
36. Majed BH, Khalil RA, (2012). Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64: 540-582.
37. Martin E, Berka V, Tsai AL, Murad F, (2005). Soluble guanylyl cyclase: the nitric oxide receptor. In: {0} (eds), Part E, Aec LP,. Nitric Oxide. Academic Press, pp. 478-492.
38. Masini E, Bani D, Bello MG, Bigazzi M, Mannaioni PF, Sacchi TB, (1997). Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide. Endocrinology 138: 4713-4720.
39. Masini E, Zagli G, Ndisang JF, Solazzo M, Mannaioni PF, Bani D, (2002). Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway. Br J Pharmacol 137: 337-344.
40. McGuane JT, Danielson LA, Debrah JE, Rubin JP, Novak J, Conrad KP, (2011a). Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans. Hypertension 57: 1151-1160.
41. McGuane JT, Debrah JE, Sautina L, Jarajapu YPR, Novak J, Rubin JP, et al., (2011b). Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786-2796.
42. Novak J, Danielson LA, Kerchner LJ, Sherwood OD, Ramirez RJ, Moalli PA, et al., (2001). Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 107: 1469-1475.
43. Palmer RM, Ferrige AG, Moncada S, (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-526.
44. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
45. Ponikowski P, Mitrovic V, Ruda M, Fernandez A, Voors AA, Vishnevsky A, et al., (2013). A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. Eur Heart J 35: 431-441.
46. Quattrone S, Chiappini L, Scapagnini G, Bigazzi B, Bani D, (2004). Relaxin potentiates the expression of inducible nitric oxide synthase by endothelial cells from human umbilical vein in in vitro culture. Mol Hum Reprod 10: 325-330.
47. Radomski MW, Palmer RM, Moncada S, (1987). The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 92: 639-646.
48. Rodenwaldt B, Pohl U, de Wit C, (2007). Endogenous and exogenous NO attenuates conduction of vasoconstrictions along arterioles in the microcirculation. Am J Physiol Heart Circ Physiol 292: H2341-H2348.
49. Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ, (2014). Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins. Br J Pharmacol 172: 1005-1019.
50. Segal MS, Sautina L, Li S, Diao Y, Agoulnik AI, Kielczewski J, et al., (2012). Relaxin increases human endothelial progenitor cell NO and migration and vasculogenesis in mice. Blood 119: 629-636.
51. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al., (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381: 29-39.
52. Voors A, Dahlke M, Meyer S, Stepinska J, Gottlieb S, Jones A, et al., (2014). Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study. Circ Heart Fail 7: 994-1002.
53. Voors A, Davison B, Felker M, Ponikowski P, Unemori E, Cotter G, et al., (2011). Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail 13: 961-967.